{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:07:23Z","timestamp":1794031643013,"version":"4.8.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tjpad.2025.100150","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T23:03:00Z","timestamp":1743289380000},"page":"100150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":282,"title":["Donanemab: Appropriate use recommendations"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-4265","authenticated-orcid":false,"given":"G.D.","family":"Rabinovici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-9767","authenticated-orcid":false,"given":"D.J.","family":"Selkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-5838","authenticated-orcid":false,"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-7727","authenticated-orcid":false,"given":"S.B.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0942","authenticated-orcid":false,"given":"S.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0001","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.tjpad.2025.100150_bib0002","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100150_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA,"},{"key":"10.1016\/j.tjpad.2025.100150_bib0004","unstructured":"FDA, U.S. 2023 [cited 2024 December 31]; Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease."},{"issue":"24","key":"10.1016\/j.tjpad.2025.100150_bib0005","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","article-title":"Mass spectrometry of purified amyloid beta protein in Alzheimer's disease","volume":"267","author":"Mori","year":"1992","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100150_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0007","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100150_bib0008","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1002\/alz.13785","article-title":"Generating real-world evidence in Alzheimer's disease: considerations for establishing a core dataset","volume":"20","author":"Galvin","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100150_bib0009","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0091","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100150_bib0010","article-title":"The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care","author":"Dickerson","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100150_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14333","article-title":"Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care","author":"Atri","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100150_bib0012","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jalz.2017.01.014","article-title":"Consensus classification of posterior cortical atrophy","volume":"13","author":"Crutch","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0013","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0014","doi-asserted-by":"crossref","first-page":"fcaa068","DOI":"10.1093\/braincomms\/fcaa068","article-title":"Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes","volume":"2","author":"Townley","year":"2020","journal-title":"Brain Commun"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100150_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.25968","article-title":"Diagnostic accuracy of amyloid versus (18) F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia","volume":"89","author":"Lesman-Segev","year":"2021","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100150_bib0017","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/alz.13729","article-title":"Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage","volume":"20","author":"Joseph-Mathurin","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0018","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jalz.2017.03.007","article-title":"Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease","volume":"13","author":"Carmona-Iragui","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100150_bib0019","article-title":"Main features of hereditary cerebral amyloid angiopathies: a systematic review","volume":"3","author":"Biffi","year":"2022","journal-title":"Cereb Circ Cogn Behav"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100150_bib0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamaneurol.2024.2579","article-title":"Lecanemab and vascular-amyloid deposition in brains of people with Down syndrome","volume":"81","author":"Liu","year":"2024","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0021","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/jgs.18124","article-title":"Conversion between the Montreal Cognitive Assessment and the mini-mental Status Examination","volume":"71","author":"Fasnacht","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0022","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/jgs.14779","article-title":"Multicenter validation of an MMSE-MoCA conversion table","volume":"65","author":"Bergeron","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0023","doi-asserted-by":"crossref","first-page":"e14335","DOI":"10.1002\/alz.14335","article-title":"The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): validated clinical assessment instruments","volume":"21","author":"Atri","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100150_bib0092","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0024","doi-asserted-by":"crossref","first-page":"1-15.e1-4","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"Suppl 1","key":"10.1016\/j.tjpad.2025.100150_bib0025","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.tjpad.2025.100150_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0027","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","article-title":"Association of beta-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"van der Kall","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100150_bib0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [(11)C]PIB-PET centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0029","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-022-01003-w","article-title":"The cerebrospinal fluid biomarker ratio Abeta42\/40 identifies amyloid positron emission tomography positivity better than Abeta42 alone in a heterogeneous memory clinic cohort","volume":"14","author":"Amft","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0030","doi-asserted-by":"crossref","first-page":"e12405","DOI":"10.1002\/dad2.12405","article-title":"Predicting continuous amyloid PET values with CSF and plasma Abeta42\/Abeta40","volume":"15","author":"Wisch","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0031","doi-asserted-by":"crossref","first-page":"e12190","DOI":"10.1002\/dad2.12190","article-title":"P-tau\/Abeta42 and Abeta42\/40 ratios in CSF are equally predictive of amyloid PET status","volume":"13","author":"Campbell","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0032","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","article-title":"Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration","volume":"98","author":"Mattsson-Carlgren","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209866","article-title":"Lumipulse-measured cerebrospinal fluid biomarkers for the early detection of Alzheimer Disease","volume":"103","author":"Safransky","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0034","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100150_bib0035","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100150_bib0036","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barthelemy","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100150_bib0037","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0038","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1002\/alz.14150","article-title":"Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0039","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer's disease pathology","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"15","key":"10.1016\/j.tjpad.2025.100150_bib0040","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100150_bib0041","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0042","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of race on prediction of brain amyloidosis by plasma Abeta42\/Abeta40, phosphorylated tau, and neurofilament light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0043","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-215730","article-title":"Blood tests for Alzheimer's Disease: increasing efforts to expand and diversify research participation is critical for widespread validation and acceptance","volume":"90","author":"Karikari","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100150_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100150_bib0045","series-title":"Clinical trials in alzheimer's disease","article-title":"Assessments from Clarity AD: downstream implications of targeting protofibrils and tau as a predictive biomarker","author":"Johnson","year":"2023"},{"key":"10.1016\/j.tjpad.2025.100150_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer's Disease","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0047","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0048","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/STR.0000000000000480","article-title":"Vascular neurology Considerations for Antiamyloid Immunotherapy: a science advisory from the American Heart Association","volume":"56","author":"Greenberg","year":"2025","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0049","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100150_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2015.4078","article-title":"Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation","volume":"73","author":"Auriel","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100150_bib0051","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0052","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3174\/ajnr.A8469","article-title":"Alzheimer Disease Anti-Amyloid Immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities","volume":"46","author":"Cogswell","year":"2025","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2025.100150_bib0053","series-title":"Latest interim results from the brainshuttletm ad study, a phase ib\/iia study of trontinemab in people with alzheimer's disease","author":"Kulic","year":"2024"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0054","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","article-title":"Amyloid-related imaging abnormalities (ARIA) in clinical trials of Gantenerumab in early Alzheimer disease","volume":"82","author":"Salloway","year":"2025","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100150_bib0055","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/01.STR.32.6.1318","article-title":"A new rating scale for age-related white matter changes applicable to MRI and CT","volume":"32","author":"Wahlund","year":"2001","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100150_bib0056","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100150_bib0057","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jamaneurol.2023.4046","article-title":"APOE genotype in the era of disease-modifying treatment with monoclonal antibodies against amyloid-beta","volume":"80","author":"Ossenkoppele","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100150_bib0058","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200230","article-title":"Apolipoprotein E genetic testing in a new age of Alzheimer disease clinical practice","volume":"14","author":"Ritchie","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100150_bib0059","first-page":"11","article-title":"The effect of different Donanmeab dosing regimens on ARIA-E and amyloid lowering in adults with early symptomatic Alzheimer's disease: primary outcome results from TRAILBLAZER-ALZ6","author":"Wang","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0061","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0062","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13195-024-01640-3","article-title":"Intracerebral hemorrhage following mild ARIA-H in an APOE epsilon2 carrier receiving lecanemab","volume":"16","author":"Ji","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100150_bib0063","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ana.22134","article-title":"Variants at APOE influence risk of deep and lobar intracerebral hemorrhage","volume":"68","author":"Biffi","year":"2010","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100150_bib0064","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1212\/WNL.0000000000007818","article-title":"APOE and cortical superficial siderosis in CAA: meta-analysis and potential mechanisms","volume":"93","author":"Charidimou","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0065","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/STROKEAHA.120.032550","article-title":"Intracerebral hemorrhage incidence, mortality, and association with oral anticoagulation use: a population study","volume":"52","author":"Fernando","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0066","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0067","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100150_bib0068","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49017","article-title":"Risk of intracranial hemorrhage associated with direct oral anticoagulation vs antiplatelet therapy: a systematic review and meta-analysis","volume":"7","author":"Coyle","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tjpad.2025.100150_bib0069","unstructured":"Eli Lilly and Company. Donanemab for the treatment of patients with early symptomatic Alzheimer's Disease: sponsor briefing document. 2024; Available from: https:\/\/www.fda.gov\/media\/179167\/download."},{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0070","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00415-024-12205-7","article-title":"Cerebral microbleeds and risk of symptomatic hemorrhagic transformation following mechanical thrombectomy for large vessel ischemic stroke","volume":"271","author":"Agbonon","year":"2024","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0071","first-page":"183","article-title":"Posterior reversible encephalopathy syndrome (PRES): diagnosis and management","volume":"22","author":"Triplett","year":"2022","journal-title":"Pract Neurol"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100150_bib0072","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaneurol.2020.1782","article-title":"Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation","volume":"77","author":"Regenhardt","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100150_bib0073","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100150_bib0074","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/cti.2015.14","article-title":"Clinical development methodology for infusion-related reactions with monoclonal antibodies","volume":"4","author":"Doessegger","year":"2015","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100150_bib0076","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22f14584","article-title":"The practical importance of half-life in psychopharmacology","volume":"83","author":"Andrade","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100150_bib0077","article-title":"Aducanumab therapy to treat Alzheimer's Disease: a narrative review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100150_bib0078","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/psp4.12862","article-title":"Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease","volume":"11","author":"Hayato","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100150_bib0079","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"10452","key":"10.1016\/j.tjpad.2025.100150_bib0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet,"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100150_bib0081","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0082","doi-asserted-by":"crossref","first-page":"595","DOI":"10.14283\/jpad.2023.50","article-title":"Time saved' As a demonstration of clinical meaningfulness and illustrated using the Donanemab TRAILBLAZER-ALZ study findings","volume":"10","author":"Dickson","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100150_bib0083","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the imaging dementia-evidence for amyloid scanning (IDEAS) cohort study","volume":"79","author":"Wilkins","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0084","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jalz.2015.12.007","article-title":"Inequalities in dementia incidence between six racial and ethnic groups over 14 years","volume":"12","author":"Mayeda","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100150_bib0085","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1002\/alz.14077","article-title":"Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study","volume":"20","author":"Magana-Ramirez","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100150_bib0086","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2023.3599","article-title":"APOE genotype and Alzheimer disease risk across age, sex, and population ancestry","volume":"80","author":"Belloy","year":"2023","journal-title":"JAMA Neurol"},{"issue":"22","key":"10.1016\/j.tjpad.2025.100150_bib0087","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100150_bib0088","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3233\/JAD-215440","article-title":"Decision-making profiles and their associations with cognitive performance in mild cognitive impairment","volume":"87","author":"Zhang","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100150_bib0089","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.jamda.2021.06.034","article-title":"Decision-making in people with dementia or mild cognitive impairment: a narrative review of Decision-making tools","volume":"22","author":"Ho","year":"2021","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100150_bib0090","doi-asserted-by":"crossref","first-page":"e14338","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T12:26:15Z","timestamp":1745670375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2274580725000949"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donanemab: Appropriate use recommendations","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100150"}}